PATENT PLUS: a blinded, randomised and extension study of riociguat plus sildenafil in pulmonary arterial hypertension Source: Eur Respir J 2015; 45: 1314-1322 Year: 2015
Rationale and study design of the RESPITE trial: Riociguat clinical effects studied in pulmonary arterial hypertension (PAH) patients with insufficient treatment response to PDE-5 inhibitors (PDE-5i) Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights Year: 2015
Imatinib in pulmonary arterial hypertension, a randomized, efficacy study (IMPRES) Source: Annual Congress 2011 - Treatments for pulmonary hypertension in human and experimental models Year: 2011
Oral sildenafil treatment in children with pulmonary arterial hypertension (PAH): results of a double-blind, placebo-controlled, dose-ranging study Source: Annual Congress 2009 - Clinical management of pulmonary arterial hypertension Year: 2009
Oral sildenafil treatment in children with pulmonary arterial hypertension (PAH): results of a double-blind, placebo-controlled, dose-ranging study Source: Annual Congress 2009 - Clinical Trials: "Aerosolized Lancovutide (Moli1901)" and "Oral Sildenafil" Year: 2009
LATE-BREAKING ABSTRACT: COPD-associated severe pulmonary hypertension (COPDPH): results of a 16-weeks prospective multicenter, double-blind, placebo-controlled randomized clinical trial (RCT) [SPHERIC-1 (http://clinicaltrials.gov/ct2/show/NCT01441934)] investigating the effect of sildenafil citrate (Sld) on pulmonary vascular resistance (PVR) and PaO2. Source: Annual Congress 2013 –Pulmonary circulation: basic science Year: 2013
Randomised placebo-controlled safety and tolerability trial of FK506 (tacrolimus) for pulmonary arterial hypertension Source: Eur Respir J, 50 (3) 1602449; 10.1183/13993003.02449-2016 Year: 2017
A randomised, controlled trial of bosentan in severe COPD Source: Eur Respir J 2008; 32: 619-628 Year: 2008
PULSAR: A phase 2, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of sotatercept (ACE-011) when added to standard of care (SOC) for treatment of pulmonary arterial hypertension (PAH) Source: International Congress 2019 – Pulmonary hypertension: clinical Year: 2019
Cicletanine in pulmonary arterial hypertension (PAH): Results from a phase 2 randomized placebo-controlled trial Source: Annual Congress 2012 - Pulmonary circulation: clinical treatment Year: 2012
Use of bosentan for the treatment of pulmonary arterial hypertension in Spain: a multicenter, retrospective, observational study Source: Annual Congress 2009 - Pulmonary hypertension Year: 2009
Early treatment of borderline pulmonary arterial hypertension associated with systemic sclerosis: a randomized, controlled, double-blind, parallel group, proof-of-concept study Source: International Congress 2018 – Risk stratification in treatment of pulmonary arterial hypertension Year: 2018
PULSAR open-label extension: interim results from a phase 2 study of the efficacy and safety of sotatercept when added to standard of care for the treatment of pulmonary arterial hypertension (PAH) Source: Virtual Congress 2021 – All about pulmonary arterial hypertension Year: 2021
Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study Source: Eur Respir J 2014; 43: 1691-1697 Year: 2014
Effects of phosphodiesterase type 5 inhibitor on pulmonary hemodynamics in the patients with high altitude pulmonary hypertension (results of 12 week randomized, blind, placebo-controlled study) Source: Annual Congress 2005 - Pulmonary arterial hypertension diagnosis and therapy Year: 2005
Effect of macitentan on haemodynamics in SERAPHIN, a randomised controlled trial in pulmonary arterial hypertension (PAH) Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment Year: 2013
Effect of macitentan on morbidity and mortality in pulmonary arterial hypertension: A randomised controlled trial (SERAPHIN) Source: Annual Congress 2013 –Pulmonary circulation: treatment Year: 2013
Initial combination therapy with ambrisentan (AMB) and tadalafil (TAD) in treatment naïve patients with pulmonary arterial hypertension (PAH): Efficacy and safety in the AMBITION study intent to treat (ITT) population Source: International Congress 2015 – Pulmonary hypertension: new treatment insights Year: 2015
Pulmonary vasodilator therapy in severe COPD: a double-blind, placebo-controlled trial Source: Eur Respir J 2007; 30: Suppl. 51, 525s Year: 2007
End-points and clinical trial design in pulmonary arterial hypertension: have we made progress? Source: Eur Respir J 2009; 34: 231-242 Year: 2009